IL142900A0 - Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer - Google Patents

Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer

Info

Publication number
IL142900A0
IL142900A0 IL14290000A IL14290000A IL142900A0 IL 142900 A0 IL142900 A0 IL 142900A0 IL 14290000 A IL14290000 A IL 14290000A IL 14290000 A IL14290000 A IL 14290000A IL 142900 A0 IL142900 A0 IL 142900A0
Authority
IL
Israel
Prior art keywords
cancer
compositions
treatment
prevention
methods
Prior art date
Application number
IL14290000A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL142900A0 publication Critical patent/IL142900A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14290000A 1999-09-03 2000-08-18 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer IL142900A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38954599A 1999-09-03 1999-09-03
PCT/US2000/022806 WO2001017543A2 (en) 1999-09-03 2000-08-18 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer

Publications (1)

Publication Number Publication Date
IL142900A0 true IL142900A0 (en) 2002-04-21

Family

ID=23538715

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14290000A IL142900A0 (en) 1999-09-03 2000-08-18 Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer

Country Status (14)

Country Link
US (1) US20060019887A1 (https=)
EP (2) EP1140136B1 (https=)
JP (2) JP2003508491A (https=)
KR (1) KR20010085996A (https=)
CN (1) CN1345246A (https=)
AT (1) ATE362374T1 (https=)
AU (1) AU6788900A (https=)
CA (1) CA2349406C (https=)
DE (1) DE60034871T2 (https=)
ES (1) ES2287028T3 (https=)
HU (1) HUP0104688A3 (https=)
IL (1) IL142900A0 (https=)
WO (1) WO2001017543A2 (https=)
ZA (1) ZA200103565B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
DE69740107D1 (de) 1996-12-23 2011-03-10 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
ES2263204T5 (es) 1997-04-15 2013-10-14 Daiichi Sankyo Company, Limited Nueva proteína y proceso para producir la misma
ES2284203T5 (es) 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU762574B2 (en) 1998-05-14 2003-06-26 Immunex Corporation Method of inhibiting osteoclast activity
HUP0104126A3 (en) * 1998-10-28 2004-07-28 Sankyo Company Ltd Chuo Ku Remedies for bone metabolic errors
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
WO2002024896A2 (en) 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
MXPA03011270A (es) * 2001-06-06 2004-03-18 Immunex Corp Uso de antagonistas rank para tratar cancer.
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
US7718776B2 (en) 2002-04-05 2010-05-18 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
EP1515743A2 (en) 2002-04-10 2005-03-23 Applied Research Systems ARS Holding N.V. Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
CA2487428A1 (en) * 2002-06-07 2003-12-18 Trillium Therapeutics Inc. Cd200-receptor mediated modulation of bone development
BRPI0519008A2 (pt) * 2004-12-13 2008-12-23 Evogenix Ltd proteÍnas variantes de osteoprotegerina
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
ES2699077T3 (es) * 2009-06-12 2019-02-07 Sunovion Pharmaceuticals Inc Apomorfina sublingual
CN102242209B (zh) * 2011-07-05 2013-12-11 北京大学人民医院 基于多个基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
AU2012375257B2 (en) * 2012-03-31 2019-09-12 R-Pharm International, Limited Liability Company Osteoprotegerin derived composition and use thereof
KR20160127824A (ko) * 2014-03-06 2016-11-04 알-팜 오버씨즈, 인코포레이티드 오스테오프로테게린 유래의 rankl 억제제
KR101576904B1 (ko) * 2014-07-31 2015-12-14 (주)케어젠 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도
EP3535585A1 (en) * 2016-11-04 2019-09-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
CN110483647B (zh) * 2019-08-19 2021-02-09 重庆大学附属肿瘤医院 一种抗肿瘤多肽及其应用
JP2023525960A (ja) * 2020-04-15 2023-06-20 セラダプティブ インク 骨に標的治療薬を送達するための組成物および方法
KR20230118573A (ko) * 2020-11-11 2023-08-11 에이치큐 한 액티빈/tgf-베타 및 rankl의 이작용성 길항제 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
AU610083B2 (en) * 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
FR2640537B1 (fr) * 1988-12-21 1992-02-21 Levy Guy Installation et procede utilisant l'effet laser, pour la coupe ou la vaporisation de materiaux et tissus divers
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3507486B2 (ja) * 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
ATE311895T1 (de) * 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
US20030207827A1 (en) * 1995-12-22 2003-11-06 William J. Boyle Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US7005413B1 (en) * 1995-12-22 2006-02-28 Amgen Inc. Combination therapy for conditions leading to bone loss

Also Published As

Publication number Publication date
ZA200103565B (en) 2002-05-03
ATE362374T1 (de) 2007-06-15
EP1140136A2 (en) 2001-10-10
CA2349406A1 (en) 2001-03-15
HUP0104688A3 (en) 2004-07-28
HUP0104688A2 (hu) 2002-03-28
DE60034871D1 (de) 2007-06-28
AU6788900A (en) 2001-04-10
KR20010085996A (ko) 2001-09-07
CA2349406C (en) 2011-01-11
DE60034871T2 (de) 2008-01-17
ES2287028T3 (es) 2007-12-16
WO2001017543A3 (en) 2001-07-26
WO2001017543A2 (en) 2001-03-15
JP2011225581A (ja) 2011-11-10
EP1140136B1 (en) 2007-05-16
US20060019887A1 (en) 2006-01-26
EP1800691A3 (en) 2007-10-31
EP1800691A2 (en) 2007-06-27
CN1345246A (zh) 2002-04-17
JP2003508491A (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
IL142900A0 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
IL189629A0 (en) Compositions containing human ctla-4 antibodies
ZA200109073B (en) Compositions for treatment of disorders of the oesophagus.
EP1128832A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND RELATED DISEASES
IL129592A0 (en) 5-HT1f agonists
WO2003008583A3 (en) Novel compositions and methods for cancer
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
PL330496A1 (en) Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy
WO2003045230A3 (en) Novel compositions and methods for cancer
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
WO2003057146A3 (en) Novel compositions and methods for cancer
MXPA00007394A (es) Compuestos, composiciones y metodos para tratar o evitar infeccion de neumovirus y enfermedades asociadas.
EP1551388A4 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS COMPRISING THE SAME
WO2003053224A3 (en) Novel compositions and methods for cancer
IL135634A0 (en) 5-htif agonists
MXPA02001204A (es) Compuestos calciliticos.
AU3896899A (en) Compositions for the treatment of tumors, and uses thereof
ZA200109845B (en) Hair treatment compositions.
IL140044A0 (en) Compounds with growth hormone releasing properties
WO2003035837A3 (en) Novel compositions and methods for cancer
AU2003258176A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EP1472376A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF UROLOGICAL DISEASES USING 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318 , 2058 OR 6351 MO
AU2003258177A8 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases